Norio Itokawa
About
Norio Itokawa is a scholar working on Epidemiology, Hepatology and Pathology and Forensic Medicine.
According to data from OpenAlex, Norio Itokawa has authored 54 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Epidemiology, 35 papers in Hepatology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Norio Itokawa's work include Liver Disease Diagnosis and Treatment (31 papers), Hepatitis C virus research (22 papers) and Hepatitis B Virus Studies (12 papers). Norio Itokawa is often cited by papers focused on Liver Disease Diagnosis and Treatment (31 papers), Hepatitis C virus research (22 papers) and Hepatitis B Virus Studies (12 papers). Norio Itokawa collaborates with scholars based in Japan, United States and South Korea. Norio Itokawa's co-authors include Masanori Atsukawa, Chisa Kondo, Akihito Tsubota, Katsuhiko Iwakiri, Taeang Arai, Tomomi Okubo, Yūji Yoshida, Noritomo Shimada, Katsuhisa Nakatsuka and Choitsu Sakamoto and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.
In The Last Decade
Norio Itokawa
49 papers receiving 514 citations
Peers
Norio Itokawa
Chisa Kondo Japan
Taeang Arai Japan
Yoshiko Kadokawa Japan
Tomomi Okubo Japan
Han Ah Lee South Korea
Yeonjung Ha South Korea
John Hsiang Singapore
Mona Lalehzari United States
Kunitaka Fukuizumi Japan
S.G. Hübscher United Kingdom
Citations per year, relative to Norio Itokawa Norio Itokawa (= 1×)
peers
Chisa Kondo
Countries citing papers authored by Norio Itokawa
Since
Specialization
Citations
This map shows the geographic impact of Norio Itokawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norio Itokawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norio Itokawa more than expected).
Fields of papers citing papers by Norio Itokawa
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Norio Itokawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norio Itokawa. The network helps show where Norio Itokawa may publish in the future.
Co-authorship network of co-authors of Norio Itokawa
This figure shows the co-authorship network connecting the top 25 collaborators of Norio Itokawa. A scholar is included among the top collaborators of Norio Itokawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norio Itokawa. Norio Itokawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Miwa, Chihiro, Sadahisa Ogasawara, Tomomi Okubo, et al.. (2025). Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy. Cancer Medicine. 14(5). e70642–e70642.
2.
Okubo, Tomomi, Masanori Atsukawa, Akihito Tsubota, et al.. (2024). Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease. PLoS ONE. 19(3). e0299313–e0299313.
3.
Okubo, Tomomi, Toru Setsu, Norio Itokawa, et al.. (2024). Esophageal Varices as an Independent Predictor of Fatal Outcomes after Balloon-Occluded Retrograde Transvenous Obliteration in Patients with Hepatic Encephalopathy. Digestive Diseases. 42(6). 583–592.
4.
Atsukawa, Masanori, Tomomi Okubo, Taeang Arai, et al.. (2023). Impact of oral semaglutide on liver pathology and glucose metabolism in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. Journal of Hepatology. 78. S818–S818.
5.
Atsukawa, Masanori, Akihito Tsubota, Yuichi Tamura, et al.. (2023). How do the 2022 European Society of Cardiology /European Respiratory Society guidelines modify the diagnosis of portopulmonary hypertension in patients with cirrhosis complicated by portal hypertension? A post hoc analysis. JGH Open. 7(8). 588–590.
6.
Atsukawa, Masanori, Akihito Tsubota, Noritomo Shimada, et al.. (2022). Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease. Scientific Reports. 12(1). 7311–7311.
7.
Omori, Jun, Osamu Goto, Yumiko Ishikawa, et al.. (2022). Prophylactic clip closure for mucosal defects is associated with reduced adverse events after colorectal endoscopic submucosal dissection: a propensity-score matching analysis. BMC Gastroenterology. 22(1). 139–139.
8.
Shirakabe, Akihiro, Hirotake Okazaki, M. Matsushita, et al.. (2022). Type III Procollagen Peptide Level can Indicate Liver Dysfunction Associated with Volume Overload in Acute Heart Failure. ESC Heart Failure. 9(3). 1832–1843.
9.
Atsukawa, Masanori, Chisa Kondo, Tomomi Okubo, et al.. (2021). Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease. Journal of Nippon Medical School. 88(3). 163–170.
10.
Wada, Naohisa, Haruki Uojima, Takashi Satoh, et al.. (2020). Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Digestive Diseases. 39(3). 234–242.
11.
Kato, Keizo, Noritomo Shimada, Masanori Atsukawa, et al.. (2019). Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. PLoS ONE. 14(7). e0219022–e0219022.
12.
Okubo, Tomomi, Masanori Atsukawa, Akihito Tsubota, et al.. (2018). Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatology International. 12(2). 133–142.
13.
Uojima, Haruki, Yoshitaka Arase, Norio Itokawa, et al.. (2018). Relationship between response to lusutrombopag and splenic volume. World Journal of Gastroenterology. 24(46). 5271–5279.
14.
Atsukawa, Masanori, Akihito Tsubota, Tomomi Okubo, et al.. (2017). Serum Wisteria floribunda agglutinin‐positive Mac‐2 binding protein more reliably distinguishes liver fibrosis stages in non‐alcoholic fatty liver disease than serum Mac‐2 binding protein. Hepatology Research. 48(6). 424–432.
15.
Atsukawa, Masanori, Akihito Tsubota, Chisa Kondo, et al.. (2017). Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Digestive and Liver Disease. 49(9). 1029–1035.
16.
Atsukawa, Masanori, Akihito Tsubota, Noritomo Shimada, et al.. (2014). Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Digestive and Liver Disease. 46(8). 738–743.
17.
Atsukawa, Masanori, Akihito Tsubota, Noritomo Shimada, et al.. (2014). Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. European Journal of Gastroenterology & Hepatology. 26(7). 781–787.
18.
Atsukawa, Masanori, Akihito Tsubota, Noritomo Shimada, et al.. (2013). Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepatitis Monthly. 13(12). e14872–e14872.
19.
Kondo, Chisa, Masanori Atsukawa, Akihito Tsubota, et al.. (2012). An open‐label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. Journal of Viral Hepatitis. 19(9). 615–622.
20.
Matsushita, Yoko, Yoshiyuki Narahara, Shunji Fujimori, et al.. (2012). Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension. Journal of Gastroenterology. 48(5). 633–639.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chisa Kondo Breakdown of academic impact, for papers by Taeang Arai Breakdown of academic impact, for papers by Yoshiko Kadokawa Breakdown of academic impact, for papers by Tomomi Okubo Breakdown of academic impact, for papers by Han Ah Lee Breakdown of academic impact, for papers by Yeonjung Ha Breakdown of academic impact, for papers by John Hsiang Breakdown of academic impact, for papers by Mona Lalehzari Breakdown of academic impact, for papers by Kunitaka Fukuizumi Breakdown of academic impact, for papers by S.G. Hübscher